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Abstract 
Background: Impaired actin–myosin cross‑bridge (CB) dynamics correlate with impaired left ventricular (LV) func‑
tion in early diabetic cardiomyopathy (DCM). Elevated expression and activity of Rho kinase (ROCK) contributes to 
the development of DCM. ROCK targets several sarcomeric proteins including myosin light chain 2, myosin binding 
protein‑C (MyBP‑C), troponin I (TnI) and troponin T that all have important roles in regulating CB dynamics and con‑
tractility of the myocardium. Our aim was to examine if chronic ROCK inhibition prevents impaired CB dynamics and 
LV dysfunction in a rat model of early diabetes, and whether these changes are associated with changes in myofila‑
ment phosphorylation state.
Methods: Seven days post‑diabetes induction (65 mg/kg ip, streptozotocin), diabetic rats received the ROCK inhibi‑
tor, fasudil (10 mg/kg/day ip) or vehicle for 14 days. Rats underwent cardiac catheterization to assess LV function 
simultaneous with X‑ray diffraction using synchrotron radiation to assess in situ CB dynamics.
Results: Compared to controls, diabetic rats developed mild systolic and diastolic dysfunction, which was attenu‑
ated by fasudil. End‑diastolic and systolic myosin proximity to actin filaments were significantly reduced in diabetic 
rats (P < 0.05). In all rats there was an inverse correlation between ROCK1 expression and the extension of myosin CB 
in diastole, with the lowest ROCK expression in control and fasudil‑treated diabetic rats. In diabetic and fasudil‑treated 
diabetic rats changes in relative phosphorylation of TnI and MyBP‑C were not significant from controls.
Conclusions: Our results demonstrate a clear role for ROCK in the development of LV dysfunction and impaired CB 
dynamics in early DCM.
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Background
Diabetes mellitus is a rapidly escalating global epidemic 
with the International Diabetes Federation predicting 
that the global incidence of diabetes will rise to 552 mil-
lion people by 2030 [1]. The most common complica-
tion of diabetes is cardiovascular disease and, is a leading 
cause of morbidity and mortality in patients [2]. More 
specifically, diabetes is associated with impaired myocar-
dial function, independent of coronary vascular disease 
and hypertension, and termed diabetic cardiomyopathy 
(DCM) [3]. In general, DCM has been recognized by 
impaired left ventricular (LV) isovolumetric (active) and 
passive relaxation, myocardial fibrosis and cardiomyo-
cyte hypertrophy [4]. However, four decades of extensive 
research on experimental animal models and significant 
advances in cardiac clinical imaging now suggests that 
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DCM is a progressive disease, with LV contractile dys-
function beginning early in the time course of diabetes, 
ahead of structural remodeling [5]. Subcellular alterations 
to the cardiomyocyte such as diminished Ca2+ handling 
ability, reduced ATPase activity and sarcomeric dysfunc-
tion might all contribute to LV contractile dysfunction in 
early diabetes [6, 7].
Utilizing synchrotron radiation as a source for small 
angle X-ray scattering (SAXS), we have recently reported 
impaired actin–myosin cross-bridge (CB) dynamics in 
the in  situ beating heart, 3  weeks post streptozotocin 
(STZ)-induced diabetes in rats [8]. We demonstrated that 
in the hearts of diabetic rats, myosin heads are displaced 
away from the actin thin-filament during diastole, lead-
ing to suppressed systolic myosin transfer to actin, and 
an assumed reduction in strong CB formation as the rate 
of pressure development was decreased [8]. Given that 
myosin interfilament spacing did not differ between the 
groups, we speculated that LV contractile dysfunction 
driven by impaired CB dynamics in early diabetes might 
be attributed to a reduction in the activity of myosin 
accessory proteins, myosin light chain-2 (MLC-2) or car-
diac myosin binding protein-C (MyBP-C), which meticu-
lously regulate myosin head extension on a beat-to-beat 
basis [9–13].
The Rho kinases (ROCK), ROCK1 and ROCK2 are 
Rho-associated kinases activated by the small GTP-bind-
ing protein RhoA. The RhoA/ROCK pathway is involved 
in a diverse range of cellular processes in the cardiovascu-
lar system, although of particular interest is the vital role 
that ROCK plays in regulating CB dynamics in vascular 
smooth muscle and cardiac muscle cells [14]. ROCK has 
been widely implicated in various animal models of dia-
betic [15, 16] and non-diabetic diastolic LV dysfunction 
[17–19]. Importantly, a recent clinical study highlighted 
the beneficial effects of short-term fasudil (a specific 
ROCK inhibitor) therapy on improving both active (iso-
volumetric) and passive myocardial relaxation in diabetic 
patients [20]. Others have reported that ROCK directly 
phosphorylates several thick and thin filament contractile 
proteins including MyBP-C, MLC-2, troponin I (TnI) and 
troponin T (TnT), and might be involved in myofilament 
dysfunction [21]. This may in part, explain improved 
active diastolic function in diabetic patients treated with 
fasudil for 2 weeks [20].
A prolonged rate of active relaxation is an established 
feature of early DCM, even as early as 2–3  weeks post 
STZ diabetes induction in rats [22, 23]. Reduced myo-
sin head extension is correlated with impaired LV active 
relaxation [8] and we have shown elevated myocardial 
ROCK expression with diabetic coronary dysfunction 
[24]. Therefore, we examined if ROCK inhibition with 
fasudil restored CB dynamics and subsequently LV func-
tion in the STZ rat model at an early stage of DCM, and 
whether these changes are associated with changes in 
ROCK expression and myofilament phosphorylation 
state in isolated cardiac tissues.
Methods
Animals
Reporting of animal studies in this paper comply with 
the ARRIVE guidelines for animal research [25]. All 
animal experiments were approved by the local Animal 
Ethics Committees and conducted in accordance with 
the National Health and Medical Research Council of 
Australia Code of Conduct for the Care of Animals for 
Scientific Purposes and the guidelines of the Physiologi-
cal Society of Japan. Two independent cohorts of male 
Sprague–Dawley rats (7–8  weeks old) were sourced 
from Animal Resources Centre (Perth, WA, Australia) 
for global cardiac function and protein phosphoryla-
tion studies (Experiment 1) or Japan SLC (Kyoto, Japan) 
for synchrotron small angle X-ray scattering (SAXS) 
(Experiment 2). Both cohorts of rats randomly received 
either a single vehicle injection of sodium citrate buffer 
(0.1 M, pH 4.5) (control) or streptozotocin (STZ; 65 mg/
kg ip) to induce type 1 diabetes. Seven days later, STZ-
injected rats were randomized to receive daily subcuta-
neous injections of the ROCK inhibitor, fasudil (10 mg/
kg/day; LC Laboratories, MA, USA) or the equivalent 
volume of the saline vehicle (1  ml/kg) and followed for 
a further 14 days. Control rats received only saline vehi-
cle injections, except in experiment 2, we also included a 
fasudil-treated control group to examine if tonic ROCK 
activation plays a role in CB disposition regulation in the 
non-diabetic heart. Body weight and blood glucose con-
centrations were measured weekly in both cohorts. Only 
rats with a blood glucose concentration >15  mmol/L 
were considered diabetic. All rats were housed in a con-
trolled environment and given access to food and water 
ad libitum.
Surgical preparation of animals
Under deep surgical anesthesia (pentobarbital sodium; 
60 mg/kg, ip), confirmed by the complete absence of the 
pedal reflex, rats were intubated and artificially ventilated 
(~40% O2; 10  ml/kg). Rats were constantly monitored 
as previously described [26] and supplemental doses of 
pentobarbital were administered throughout the experi-
ments to maintain adequate anesthesia. In experiment 
2, pancuronium bromide was also used in addition after 
confirming an adequate depth of anesthesia to eliminate 
spontaneous breathing while the ventilator was briefly 
switched off during recordings [26]. Body temperature 
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was maintained at 37°C throughout the experimental 
protocol with the use of a rectal thermistor coupled with 
a thermostatically controlled heating pad.
Experiment 1
Briefly, the right carotid artery was isolated and cath-
eterized with a 2Fr pressure–volume (PV) conductance 
catheter (SPR-838, Millar Instruments, TX, USA) and 
advanced retrograde into the LV. The left jugular vein 
was also cannulated for fluid replacement and hyper-
tonic saline bolus infusion. Subsequently, the abdomen 
was opened and loose ligatures placed around the infe-
rior vena cava (IVC) and portal vein to facilitate pre-load 
reduction [27].
Experiment 2
For synchrotron SAXS studies, rats underwent a thora-
cotomy to allow an unobstructed path to the heart. A 
continuous drip-flow of lactate Ringers solution was used 
to prevent the drying of the exposed heart and lungs. A 
PV catheter was advanced into the LV as described above 
to allow simultaneous recording of SAXS and PV data 
[8]. The right jugular vein was then cannulated for fluid 
replacement and to maintain a stable blood and LV vol-
ume. The right femoral artery was also cannulated for the 
continual monitoring of blood pressure. The heart was 
then partly restrained with a plastic receptacle inserted 
beneath the posterior apex to ensure maintenance of 
myocardial depth during imaging experiments [26, 28].
Experiment 1 protocol
Load-dependent and load-independent measures of car-
diac function were assessed by PV loop analysis [29–31]. 
Continuous PV loop monitoring was performed through-
out the experiments however, for PV loop recordings, 
the ventilator was switched off briefly (~5  s) with the 
rat apneic to reduce breathing motion artifacts. PV data 
were acquired under steady state conditions and during 
preload reduction by the occlusion of the IVC and por-
tal vein by methods previously described [30, 31]. The 
volume signal was calibrated by the validated hyper-
tonic saline method [32]. PV data were recorded using 
CHART (v5.5.6, AD Instruments, NSW, Australia) and 
subsequently analyzed offline using PVAN (v3.5, Millar 
Instruments).
Experiment 2 SAXS system and protocol
X‑ray source, camera and diffraction recordings
Experiments were conducted at Beamline 40XU at the 
Japanese Synchrotron Radiation Research Institute 
(SPring-8), Hyogo, Japan. In brief, the myocardial sur-
face was aligned at an oblique tangent to a collimated 
quasi-monochromatic X-ray beam with the dimensions, 
wavelength and flux as previously described [8, 26, 28] 
with the rat approximately 3  m away from the detector 
[8, 28]. SAXS patterns (<2.1  s) were acquired at 15  ms 
intervals using an image intensifier (V5445P, Hamamatsu 
Photonics, Hamamatsu, Japan) and a fast charge-coupled 
device camera (C4880-80-24A, Hamamatsu Photonics). 
Diffraction patterns were recorded using HiPic32 acqui-
sition software (v5.1.0, Hamamatsu Photonics).
Protocol
SAXS recordings were obtained during an intravenous 
infusion of lactate (4  ml/h; lactate Ringers solution, 
Otsuka Pharmaceuticals, Osaka, Japan). Rats were then 
killed with a potassium chloride (KCl) bolus (0.1  M) 
to arrest the heart in diastole. SAXS patterns were 
also recorded post-KCl administration during muscle 
quiescence.
X‑ray diffraction pattern analysis
SAXS patterns were analyzed using an in-house designed 
software (X-RAT) utilizing commercial visualization 
tools and algorithms (IDL8.2, Exelis, VA, USA). Myo-
filament lattice spacing calibration was made using the 
63.5 nm meridional reflection from a dried chicken ten-
don at the beginning of experiments. SAXS sequences 
were loaded into X-RAT and the arc radians of the 1,0 
and 1,1 equatorial reflections specified from the image 
center. A manual second order polynomial curve fitting 
was performed within user defined inner and outer lim-
its. The integrated intensity of the 1,0 and 1,1 reflection 
intensities were then determined by the areas under the 
reflection peaks, defined as I1,0 and I1,1, respectively. The 
integrated intensity of the 1,1 reflection was then cor-
rected by a √3 multiplication as previously discussed by 
Jenkins et al. [8] prior to analysis. As the number of fibers 
in the beam path changes during contraction the equa-
torial intensity ratio (I1,0/I1,1) was used to determine the 
transfer of myosin mass, presumed to be CBs, from the 
thick to the thin filament. The 1,0 reflection lattice spac-
ing (d1,0) was obtained from the center of gravity of the 
integrated 1,0 reflection at end diastole and maximum 
systolic spacing.
Radial transfer of myosin heads to actin was calcu-
lated as an absolute measure of myosin mass transfer 
based on the methods previously described [8]. Briefly, 
intensity ratios during complete muscle quiescence 
(post KCl administration) and the minimum attainable 
intensity ratio of 0.2 during rigor state (maximum actin 
binding site occupancy) in both control and diabetic 
hearts were obtained. Linear regression was then per-
formed to interpolate the peak systolic and end-dias-
tolic myosin mass transfer to actin (% of maximum in 
rigor state) [8].
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Tissue collection
At the conclusion of all experiments, hearts were rapidly 
excised and sliced transversely. The apex portion minced 
and snap-frozen in liquid nitrogen and stored at −80°C 
and the remainder was fixed in 4% paraformaldehyde.
Histology
Sections of 4  μm thickness were stained with hema-
toxylin and eosin (H&E) to assess cardiomyocyte cross-
sectional area in approximately 30 single nucleated cells 
in each section. Picrosirius red was used to investigate 
LV interstitial fibrosis. All histological sections were 
imaged using the Aperio ScanScope XT Slide Scanner 
(Aperio Technologies, CA, USA). The proportional area 
of positive staining was quantified using the Positive Pixel 
Count algorithm (v9.1) on Aperio ImageScope software.
Tissue preparation for SDS–PAGE and Western blotting
At least 100 mg of LV tissues were homogenised in ice-
cold lysis buffer containing protease and phosphatase 
inhibitors. The protein concentration of each sample was 
determined using a Bradford protein assay.
Myofilament protein phosphorylation
Approximately 10 μg of protein was loaded per sample. 
Proteins were then subjected to SDS–PAGE using Bio-
Rad AnykD ™ (Bio-Rad, CA, USA) gradient mini-gels. 
Gels were then fixed, washed and stained with a spe-
cific phosphoprotein stain, Pro-Q Diamond (Invitrogen, 
OR, USA) according to the manufacturers protocol and 
imaged using a ChemiDoc MP imager system (Bio-Rad). 
After imaging, gels were then post-stained with SYPRO 
Ruby (Invitrogen) overnight for total protein. Relative 
phosphorylation of myofilament proteins were deter-
mined by dividing the Pro-Q Diamond signal by the 
SYPRO Ruby total protein signal [33].
Western blotting
For western blotting, 30–75  μg of protein was loaded 
on 7.5 or 12% polyacrylamide mini-gels, subjected to 
SDS–PAGE and subsequently transferred onto PVDF 
membranes. After blocking with 5% non-fat milk, mem-
branes were incubated in primary antibodies against 
ROCK1 (1:500), ROCK2 (1:200) (Abcam, Cambridge, 
UK), pRhoASer188 (1:1,000) and RhoA (1:1,000) (San-
taCruz Biotechnology, CA, USA) at 4°C overnight [34]. 
Following incubation in an anti-rabbit HRP conjugated 
secondary antibody (Dako, Glostrup, Denmark; 1:2,500) 
for 1  h at room temperature, proteins were detected 
using the ECL detection method. Membranes were then 
re-probed with β-actin (Abcam, 1:1,000) or GAPDH 
(Abcam, 1:10,000), which served as a loading control. 
Bands were analysed by densitometry using Image Lab 
Software (Bio-Rad).
Statistical analysis
All data is expressed as mean ±  SEM unless otherwise 
stated. Differences between groups were assessed by a 
one-way ANOVA with a Fischer’s least significant dif-
ference post hoc test. Linear regression was performed 
to test for significant correlations. All statistical analysis 
were performed using GraphPad Prism (v6.0, Graph-




The administration of STZ to rats in both experimen-
tal cohorts resulted in a significant three to four fold 
increase in fasting blood glucose concentrations and a 
significantly lower body weight compared to control rats 
(Table  1; Additional file  1: Table S1). Fasudil treatment 
in control and diabetic rats did not affect blood glucose 
concentration or body weight. In experiments 1 and 2, 
LV weights tended to be lower in diabetic rats compared 
to their control counterparts. When normalized to body 
weight (LV:BW ratio) however, no significant difference 
was observed between all groups in either experimen-
tal cohort (Table 1; Additional file 1: Table 1). Similarly, 
mean arterial pressure of rats did not significantly differ 
Table 1 General characteristics of rats from experiment 2
Data expressed as mean ± SEM.
* P < 0.05, ** P < 0.01 and ## P < 0.0001 vs. control rats.
Control Control + fasudil Diabetic Diabetic + fasudil
N 5 4 7 7
Body weight (g) 381 ± 6 384 ± 17 300 ± 20** 275 ± 17#
Fasted blood glucose (mmol/L) 7.3 ± 0.3 7.5 ± 0.1 28.5 ± 1.8## 32.3 ± 0.7##
Mean arterial pressure (mmHg) 95.8 ± 5.5 105.3 ± 9.2 83.9 ± 7.3 94.4 ± 10.9
Left ventricle weight (g) 0.76 ± 0.02 0.74 ± 0.03 0.66 ± 0.06 0.59 ± 0.04#
Left ventricle weight:body weight (mg/g) 2.0 ± 0.08 1.9 ± 0.04 2.3 ± 0.04 2.2 ± 0.13
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amongst the groups in either experimental cohort 
(Table 1; Additional file 1: Table S1).
Myocardial structure
Cardiomyocyte cross-sectional area did not significantly 
differ across all groups in rats from either experiment, 
indicating that cardiac hypertrophy was not found in 
the diabetic groups (Additional file  1: Figure  S1, shown 
for experiment 2) Similarly, LV interstitial collagen ratio 
(fibrosis scores) were similar among the groups in both 
experimental cohorts (Additional file 1: Figure S2).
Global left ventricular function: experiment 1
In comparison to control rats, diabetic rats exhibited 
a ~17% reduction in heart rate (350 ± 12 vs. 290 ± 12, 
P  <  0.01, Table  2). Diabetic rats treated with fasudil 
maintained a significantly lower heart rate to that of 
control rats (350 ±  12 vs. 299 ±  13, P  <  0.01, Table  2). 
Three weeks of STZ-induced diabetes resulted in mild 
systolic dysfunction compared to controls, evident 
as a suppressed LV end systolic pressure (127  ±  6 vs. 
95 ± 9 mmHg, P < 0.01, Table 2), a significant 35% reduc-
tion in preload recruitable stroke work (PRSW; 74 ± 10 
vs. 48 ± 4 mmHg, P < 0.05, Table 3) in addition to non-
significant 46% and 35% reductions in the end-systolic 
pressure volume relationship (ESPVR) and the relation-
ship of the rate of pressure development and ED vol-
ume (dP/dt-EDV), respectively (Table 3). Impairment in 
LV active relaxation was also found in diabetic rats evi-
denced by a prolonged mean rate of LV pressure decay 
(dP/dtminimum, P  <  0.05, Table  2) and increased mean 
Tau relaxation time (12 ± 0.3 vs. 14.4 ± 0.7 ms, P < 0.05, 
Table  2) when compared to controls. Passive compli-
ance of the diabetic heart did not differ from that of 
controls as demonstrated by similar LV ED pressures 
(7.5 ± 0.9 vs. 7.8 ± 1 mmHg, NS, Table 1) and ED pres-
sure volume relationships (EDPVR; 0.03  ±  0.005 vs. 
0.02 ± 0.001 mmHg/μl, NS, Table 3).
The systolic dysfunction associated with diabetes was 
alleviated in diabetic rats treated with fasudil, as no sig-
nificant difference in end systolic pressure or PRSW 
(Tables 2, 3) was found when compared to control rats. In 
contrast, impairment in active diastolic relaxation asso-
ciated with diabetes was not significantly improved by 
fasudil. Although there was a ~10% increase in the rate 
of pressure decay in diabetic rats treated with fasudil in 
comparison to vehicle treated diabetic rats, LV pressure 
decay rate was significantly prolonged when compared 
with controls (dP/dtminimum, Table 2).
Rho kinase expression and myofilament protein 
phosphorylation in the left ventricle: experiment 1
On average ROCK1 expression (Figure  1a) in the LV 
of diabetic group was ~19% higher than the control 
group (0.32 ±  0.08 vs. 0.26  ±  0.06 AU, NS, Figure  1c). 
Chronic treatment of diabetic rats with fasudil resulted 
in a ~48% lower ROCK1 expression in comparison to 
vehicle treated diabetic rats (0.18 ± 0.04 vs. 0.32 ± 0.08 
AU, NS, Figure  1c). LV ROCK2 expression (Figure  2a) 
was elevated ~2.5-fold in diabetic rats, although this 
did not reach statistical significance (0.015  ±  0.005 
vs. 0.006 ±  0.005 AU, Figure  2c). Two weeks of fasudil 
tended to reduce ROCK2 expression in the diabetic heart 
(0.015  ±  0.005 vs. 0.010  ±  0.002 AU, NS, Figure  2c). 
Thus, ROCK expression was not consistently increased in 
early diabetes as has been reported in advanced states of 
diabetes [35].
Three weeks of STZ-induced diabetes in rats resulted 
in a ~23% lower MyBP-C phosphorylation compared 
to control rats, which was partially attenuated by fasudil 
Table 2 Load dependent indices of left ventricular function 
as measured by pressure–volumetry from Experiment 1
Data expressed as mean ± SEM.
dP/dtmaximum, maximum rate of left ventricular pressure development;  
dP/dtminimum, minimum rate of left ventricular pressure decay.
* P < 0.05 and ** P < 0.01 vs. control rats.
Control Diabetic Diabetic + fasudil
Heart rate (BPM) 350 ± 12 290 ± 12** 299 ± 13**
End systolic pressure 
(mmHg)
127 ± 6 95 ± 9** 115 ± 5
End diastolic pres‑
sure (mmHg)
7.5 ± 0.9 7.8 ± 1 8.7 ± 1
Stroke volume (μl) 168 ± 20 184 ± 8 193 ± 17
Cardiac output (ml/
min)
59.4 ± 8.1 53.5 ± 3.5 57.7 ± 5.6
Ejection fraction (%) 66 ± 8 60 ± 7 50 ± 3
dP/dtmaximum 
(mmHg/s)
7,391 ± 602 6,616 ± 470 7,096 ± 641
dP/dtminimum 
(mmHg/s)
−8,210 ± 632 −5,917 ± 502* −6,439 ± 569*
Tau Glantz (ms) 12 ± 0.3 14.4 ± 0.7* 14.2 ± 0.8*
Table 3 Load-independent cardiac indices as  measured 
by left ventricular pressure-volumetry from Experiment 1
Data expressed as mean ± SEM.
ESPVR, end systolic pressure volume relationship; PRSW, preload recruitable 
stroke work; EDPVR, end diastolic pressure volume relationship; dP/dt-EDV, 
relationship of rate of pressure development and end diastolic volume.
* P < 0.05 vs. control.
Control Diabetic Diabetic + fasudil
ESPVR (mmHg/μl) 0.52 ± 0.15 0.28 ± 0.05 0.33 ± 0.01
PRSW (mmHg) 74 ± 10 48 ± 4* 63 ± 6
EDPVR (mmHg/μl) 0.03 ± 0.005 0.02 ± 0.001 0.03 ± 0.005
dP/dt‑EDV (mmHg/s/μl) 23 ± 4 15 ± 1 22 ± 3
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(Additional file 1: Figure   S2c). MLC-2 exhibited a small 
increase in phosphorylation in the LV of the diabetic 
group only (~17%, NS Additional file 1: Figure S2d). When 
compared to control rats, a weak trend for a higher TnI 
phosphorylation was found in diabetic rats (~30% higher, 
P = 0.1254, Additional file 1: Figure S2e), while TnI phos-
phorylation was similar to that of control group levels in 
fasudil treated diabetic rats (Additional file 1: Figure S2e). 
TnT phosphorylation was similar among the control, 
diabetic and diabetic fasudil-treated groups (Additional 
file  1: Figure  S2f). Hence, the only notable trend was 
for diabetic rats to have greater phosphorylation of TnI, 
which was not found in fasudil treated diabetic rats.
Actin–myosin cross‑bridge dynamics: experiment 2
Myosin head proximity to actin thin filaments 
and interfilament spacing
In control and fasudil-treated control rats, ED (Figure 3a) 
and minimum (representative of peak systolic CB attach-
ments) intensity ratios (Figure  3b) did not significantly 
differ with respect to myocardial layer. Diabetic rats 
exhibited higher ED intensity ratios in all myocardial lay-
ers compared to control rats, and in contrast, intensity 
ratio was significantly higher in the subendocardium 
(P < 0.05, Figure 3a). Similarly, minimum intensity ratio 
in diabetic rats was higher in all myocardial layers (Fig-
ure 3b), increased with myocardial depth in comparison 
to control rats (subendocardium P < 0.05, Figure 3b). In 
diabetic rats treated with fasudil, neither ED or mini-
mum intensity ratios differed significantly from the con-
trol group, but intensity ratio over the cardiac cycle was 
intermediate between control and saline treated dia-
betic groups. Elevated intensity ratios in diabetic rats in 
general were paralleled by significantly smaller ED and 
systolic d1,0 spacings (P  <  0.05, Figure  4). Fasudil treat-
ment resulted in intermediate myosin spacings with 
the greater difference from the control group in the 
subendocardium.
Absolute myosin mass transfer
In the two control groups, ~20–60% of myosin heads 
remained in close proximity to actin at ED (Figure  5a). 
In the epicardium, both diabetic and fasudil-treated dia-
betic groups were found to have on average comparable 
myosin mass transfer to actin to that of control group 
(27 and 39%, respectively) at ED relative to quiescent and 
rigor states of cardiac muscle [27] (Figure 5a). However, 
in the subepicardium and subendocardium, ED myosin 
mass transfer from the myosin thick filament backbone 
to actin was variable between individuals and on average 
Figure 1 Rho kinase 1 (ROCK1) expression in the left ventricle. Repre‑
sentative images of western blot membranes for ROCK1 (a) and actin 
loading control (b) from control, diabetic and diabetic rats treated 
with fasudil (10 mg/kg/day). Compared to control rats, ROCK1 protein 
expression in the left ventricle of diabetic rats was similar. Fasudil 
treatment (10 mg/kg/day) in diabetic rats did not change ROCK1 
expression in the left ventricle in comparison to the diabetic group. 
Panel c is the quantification of ROCK1 expression relative to actin. 
Data expressed as mean ± SEM. N = 6 per group.
Figure 2 Rho kinase 2 (ROCK2) expression in the left ventricle. Repre‑
sentative images of western blot membranes for ROCK2 (a) and actin 
loading control (b) from control, diabetic and diabetic rats treated 
with fasudil (10 mg/kg/day). No significant changes were observed 
among the three experimental groups. Panel c is the quantification of 
ROCK2 expression relative to actin. Data expressed as mean ± SEM. 
N = 6 per group.
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zero in the diabetic group (Figure 5a). In contrast, the fas-
udil treated diabetic group maintained similar ED myosin 
mass transfer to the control group (Figure 5a), suggesting 
that ROCK may contribute to early impairment of dias-
tolic CB dynamics in the diabetic heart.
Peak systolic myosin mass transfer was maintained 
at ~80–90% in both groups of control rats in all depths 
of the LV wall (Figure 5b). In the saline treated diabetic 
group, peak systolic myosin mass transfer was ~10 and 
~8% lower in the epicardial and subepicardial layers, 
respectively in comparison to the control group (Fig-
ure  5b), while the diabetic group treated with fasudil 
exhibited similar mean peak systolic myosin mass trans-
fer to that of the control group (Figure  5b). In the sub-
endocardium, diabetic rats had a ~15% lower systolic 
myosin mass transfer compared to controls. Fasudil 
treatment of diabetic rats restored ~47% of the decrease 
in subendocardial systolic myosin mass transfer observed 
in diabetic vehicle treated group (Figure 5b).
In experiment 2, similar to the cohort in experiment 1, 
ROCK1 expression tended to be higher in the diabetic 
group and was low in the fasudil treated groups (Addi-
tional file  1: Figure  S4). Expression of the RhoA activa-
tor of ROCK did not differ significantly between groups. 
The large within group variability precluded significant 
difference in mean ROCK expression in the LV between 
groups. Nonetheless, there was a direct correlation 
between global ROCK1 expression and ED intensity 
ratio derived from the epicardium in individual rats (Fig-
ure  6). The fit of the regression for the diabetic group 
alone was similar to that of the common regression for 
all groups pooled (slope P < 0.056, r2 = 0.637 vs. pooled 
slope P < 0.0003, r2 = 0.554). This suggests that myosin 
head extension from the myosin filament is decreased as 
ROCK expression in the myocardium increases with dia-
betes progression.
Myosin head detachment in diastole
We used the rate of change in diffraction intensity ratio 
as an index of the rate of CB detachment from actin in 
early diastole. Additional file  1: Figure  S6a shows the 
rate of change in intensity ratio over the cardiac cycle for 
individual rats. In the systolic phase, the rate of change is 
negative. From 30 to 40% of the cardiac cycle, the inten-
sity ratio increases as CBs detach from actin (Additional 
file  1: Figure  S6a). The maximum rate of intensity ratio 
increase occurred at 73–75% of the cardiac cycle in con-
trol rats treated with fasudil and in both groups of dia-
betic rats, which was significantly later than in control 
rats (63 ± 2.0%, P < 0.05, Additional file 1: Figure S6b). 
Figure 3 Myosin mass transfer changes across the cardiac cycle. Mean intensity ratio (I1,0/I1,1) at end diastole (ED, a) and systolic minimum (b) in 
the epicardial, subepicardial and subendocardial layers of the left ventricle. Intensity ratio did not significantly differ between vehicle‑treated control 
and diabetic rats or fasudil‑treated (10 mg/kg/day) control and diabetic rats in the epicardium or subepicardium at either time point. In the deep 
subendocardial layer, diabetic rats had a significantly elevated ED and systolic minimum intensity ratio (P < 0.05). Data expressed as mean ± SEM. 
*P < 0.05 vs. control in the same myocardial layer. N = 4–6 per group.
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Thus, ROCK inhibition did not increase the rate of CB 
detachment.
Myosin head disposition in relation to global left ventricular 
function
ED intensity ratio in the epicardium was positively corre-
lated with the minimum rate of LV pressure decay (global 
LV relaxation) in individual diabetic vehicle treated rats 
(slope P < 0.001, r2 = 0.95, Additional file 1: Figure S7). 
An elevated ED intensity ratio in the epicardium appears 
to correlate with global diastolic dysfunction in diabetic 
rats as the rats found to have low dP/dt minimum also 
had elevated ED intensity ratios in all layers of the heart. 
No such correlation was observed in control (vehicle or 
fasudil treated) or fasudil treated diabetic groups.
Discussion
In the present study, we have observed a possible role for 
the ROCK pathway in the development of LV contractile 
dysfunction in early DCM. Our data revealed that LV 
systolic and diastolic dysfunction were associated with 
a trend for elevated expression of cardiac ROCK1 and 
ROCK2 in vehicle-treated diabetic rats, as reported by 
others [24, 35]. Importantly, we have demonstrated that 
chronic ROCK inhibition with fasudil maintained basal 
CB dynamics in diabetic rats as evidenced by preserved 
diastolic myosin mass transfer in all fiber layers of the LV 
wall. Further, chronic ROCK inhibition also partially res-
cued the suppressed subendocardial peak systolic myosin 
mass transfer observed in vehicle-treated diabetic rats. 
Fasudil exerted these beneficial effects in diabetic ani-
mals without changes in blood glucose concentrations 
or blood pressure. This suggests that the effects of ROCK 
inhibition with fasudil were found to directly target the 
myocardium and not the vasculature at this dose.
The rat model of early diabetes used in our studies 
(3 weeks post STZ-induced diabetes) allowed for the exam-
ination of early functional changes to the myocardium, 
independent of overt structural remodeling that is generally 
present in the more advanced stages of DCM [30, 36]. We 
found that cardiomyocyte cross-sectional area (indicative 
of hypertrophy) and interstitial fibrosis scores did not dif-
fer among the groups. This is consistent with our previous 
findings [24], and that of others [23] using rat models of 
early diabetes. Thus, it is likely that the mild cardiac dys-
function observed in diabetic rats at this time-point arises 
from subcellular alterations to contractile apparatus within 
the cardiomyocyte due to ROCK activation.
Figure 4 End diastolic (ED) interfilament (d1,0) spacing (a) and systolic interfilament spacing (b) from experiment 2. In comparison to control rats, 
ED and peak systolic d1,0 spacing in the was not significantly different in the epicardium between the groups. In the subepicardium, diabetic rats 
had a significantly smaller ED and systolic d1,0 spacing compared to control rats (P < 0.05). However, in the subendocardial layer, both the diabetic 
and diabetic rats treated with fasudil (10 mg/kg/day) had significantly reduced ED d1,0 spacing (P < 0.05) and systolic spacing (P < 0.01, P < 0.05, 
respectively) in comparison to control rats. Data is expressed as mean ± SEM. *P < 0.05 and **P < 0.01 vs. control in the same myocardial layer. 
N = 4–6 per group.
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Regional differences in cross‑bridge dynamics in relation 
to global cardiac function: the effects of fasudil
Our previous study has reported elevated ED and mini-
mum intensity ratios with increasing myocardial depth 
in diabetic rats, indicating regional differences in CB 
dynamics and thus, non-uniform regulation of CB 
dynamics across the LV wall in the diabetic heart [8]. In 
the present study, we confirmed these findings with the 
observation that pronounced myosin head displacement 
from actin at ED and peak systole occurred in the subepi-
cardial–subendocardial layers in diabetic rats. These data 
are supported by clinical evidence from tissue Doppler 
imaging of myocardial velocity and strain rate suggest-
ing that longitudinal contractility of the heart by the sub-
epicardial–subendocardial layers declines prior to that of 
epicardial and endocardial fibers of the heart in diabetic 
patients [37].
Systolic function and force development
Our findings demonstrate that fasudil treatment of dia-
betic rats maintains myosin heads away from the myosin 
backbone during diastole similar to that of control rats, 
in all layers of the LV wall. This is an important finding as 
early studies conducted by Matsubara and colleagues [38] 
revealed that the number of myosin projections in close 
proximity to actin during diastole is directly related to 
the developed force of subsequent contractions. There-
fore, it is conceivable that the improvements in systolic 
Figure 5 Diastolic and peak systolic myosin mass transfer. Diastolic (a) and peak systolic (b) myosin mass transfer in the epicardium, subepicardium 
and subendocardium of the left ventricle. Diastolic myosin mass transfer did not significantly differ between vehicle‑treated control and diabetic 
rats or fasudil‑treated (10 mg/kg/day) control and diabetic rats in the epicardial layer. In the subepicardial and subendocardial layers, no significant 
changes were observed in diastolic myosin mass transfer in diabetic rats compared to controls, or to fasudil‑treated diabetic rats. Peak systolic myo‑
sin mass transfer was similar in all LV layers in diabetic rats compared to controls. Fasudil treatment of diabetic rats did not change subendocardial 
systolic myosin mass transfer. Data expressed as mean ± SEM. N = 4–6 per group.
Figure 6 Correlation between ROCK1 protein expression and end 
diastolic myosin mass transfer in individual rats. ROCK1 expression in 
the left ventricle relative to the GADPH loading control is presented 
for the rats utilized in the SAXS experiment 2. End diastolic (ED) 
intensity ratio (I1,0/I1,1) is presented for the epicardial layer. A com‑
mon linear regression fitted to pooled data for all rats is shown with 
95% confidence intervals of the mean (y = 1.139x − 0.910, slope 
P < 0.0003, r2 = 0.554).
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performance and force development of diabetic rats 
treated with fasudil is likely to be a result of increased 
myosin head proximity to actin thin filaments in diastole.
In principle, differences in the interfilament spacing 
(and thus sarcomere length) could potentially explain 
the differences in ED myosin mass shifts. Previous work 
conducted by our group shows a direct inverse correla-
tion between interfilament spacing and the number of 
CBs that can form attachments in the next cardiac cycle 
[28]. In the current investigation, we have found that in 
the diabetic heart, ED interfilament spacing was signifi-
cantly smaller, in all myocardial layers, but particularly 
in the fiber layers below the epicardial surface (Figure 6). 
Therefore, a smaller interfilament spacing coincided with 
increased diffraction intensity ratio and reduced myosin 
head extension. Fasudil treatment resulted on average in 
a myosin spacing similar to control rats in the superficial 
muscle layers, but an intermediate myosin spacing per-
sisted in the subendocardium. Based on a growing body 
of evidence we considered that one possibility is that in 
diabetic rats treated with fasudil the increase in myosin 
head proximity to actin filaments is facilitated by changes 
in the phosphorylation state of the myosin accessory pro-
teins involved in the regulation of myosin head extension.
Diastolic function
ROCK activation has been implicated in the prolonged 
myocardial relaxation associated with DCM. Acute inhi-
bition of ROCK with Y-27632 or H-1152 in an isolated 
heart preparation rapidly alleviates the prolonged rates 
of LV pressure decay in rats with advanced DCM, con-
firming that ROCK drives diastolic dysfunction by direct 
actions on the sarcomere [39]. However in the present 
study, we did not observe a significant improvement in 
active relaxation during diastole in diabetic rats treated 
with fasudil. This is in contrast to a similar study, where 
Guan et  al. [15] reported a significant improvement in 
dP/dtminimum after 4  weeks of an equivalent dose of fas-
udil treatment in rats with advanced DCM (8 weeks post 
diabetes induction). The exact reason for the discrepancy 
between these studies is uncertain. One possible explana-
tion is that long-term treatment of diabetic rats with fas-
udil may be required to detect significant improvements 
in active diastolic relaxation rates. It should also be noted 
that in that study [15], measures of systemic blood pres-
sure were not presented. As elevated blood pressure is a 
reported complication of advanced STZ-induced diabe-
tes in rats [40], it is difficult to delineate if the observed 
improvements in active diastolic function in diabetic rats 
from the previous study were due to the antihyperten-
sive effects of fasudil [41], reducing cardiac loading con-
ditions or direct effects on the myocardium. However, a 
recent clinical study in a small cohort of T2DM patients 
with impaired LV relaxation has reported 2  weeks of 
twice daily fasudil treatment (30 mg twice per day, intra-
venous) significantly improved various diastolic param-
eters including E/A wave ratio, deceleration time, E/e′ 
and isovolumetric relaxation time [20], providing further 
support of a role for ROCK in the development of dias-
tolic dysfunction in DCM. Therefore, the evidence avail-
able does suggest that ROCK inhibitors improve systolic 
function in early diabetes and diastolic function at least 
in advanced diabetes.
Possible mechanisms for Rho kinase in cross‑bridge 
dysregulation
The findings of the present study corroborate those 
from our previous study that showed small increases 
in expression of myocardial ROCK1 and ROCK2 [24]. 
Importantly, ROCK protein expression is shown to be 
directly related to the degree of CB dysfunction and the 
rate of LV pressure decline in diastole in this study. Fur-
ther, chronic inhibition by fasudil at a dose of 10 mg/kg/
day prevented any increase in myocardial ROCK1 and 
ROCK2 expression in diabetic rats. Similar findings were 
found in rats from both experimental cohorts (Additional 
file 1: Figure S4). Over the past decade, ROCK has been 
identified as an emerging therapeutic target, mainly due 
to a growing body of evidence implicating ROCK in vari-
ous cardiovascular pathologies (reviewed in [42, 43]). 
Recently, it has even been shown that ROCK isoforms 
can be rapidly induced by oxidative stress and exhibit dif-
ferential protein expression throughout the LV and right 
ventricle myocardium reflecting the severity of contrac-
tile dysfunction and regional differences in the hyper-
trophic state associated with pressure overload [44]. The 
role of ROCK in the regulation of actin–myosin inter-
actions is pertinent to this study. It is well established 
in smooth muscle cells that ROCK regulates the phos-
phorylation state of MLC-2 through its interaction with 
myosin light chain phosphatase [45]. Moreover, in iso-
lated cardiomyocytes it has been shown that ROCK can 
directly phosphorylate MyBP-C [21]. X-ray diffraction 
experiments conducted on isolated cardiac muscle have 
demonstrated that increased phosphorylation of either 
MLC-2 or MyBP-C results in radial displacement of 
myosin heads away from the myosin thick-filament back-
bone toward actin [46, 47]. Therefore, it is reasonable to 
expect that decreased phosphorylation of MLC-2 and or 
MyBP-C would lead to less myosin heads in the vicin-
ity of actin in diastole. In our study, MLC-2 phospho-
rylation did not differ among the groups and the lower 
MyBP-C phosphorylation in the vehicle-treated diabetic 
group was not significant. In contrast, Chung and col-
leagues [48] found that myocardial MLC-2 phosphoryla-
tion was significantly reduced in the early diabetic heart 
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with no change in MyBP-C phosphorylation. However, 
Korte et  al. [49] have reported significant reductions in 
MyBP-C phosphorylation in the myocardium of dia-
betic swine. Moreover, deletion of MyBP-C or reduc-
tion in its phosphorylation in transgenic mouse models 
and patients carrying MyBP-C mutations causes diastolic 
dysfunction with impaired relaxation that appear to be 
primarily due to a slower CB detachment rate relative 
to attachment rate (reviewed by Tong et al. [50]). While 
diabetic rats treated with fasudil in this study had phos-
phorylation levels of MyBP-C that did not differ from the 
control group and a faster maximum rate of LV pressure 
decay than the vehicle-treated diabetic group the relaxa-
tion time constant was not shorter. Fasudil treatment did 
not influence the rate of increase in intensity ratio in the 
first period of diastole. Therefore, it is unlikely that fol-
lowing ROCK inhibition that the prolongation of active 
relaxation time can be attributed to an ATP dependent 
limitation on the rate of CB detachment, even though it 
has been suggested that ROCK activation reduces acto-
myosin ATPase activity [21]. Taken together the available 
evidence suggests that ROCK activation mediates the 
early origins of contractile dysfunction, by reducing myo-
sin head extension from the myosin backbone and reduc-
ing the probability of strong CB formation during systole. 
However, a role for altered total phosphorylation activity 
of cardiac troponins or MyBP-C in mediating the effects 
of ROCK activation in early contractile dysfunction is 
not supported by our findings. This is not to say that the 
ROCK mediated reduction in MyBP-C phosphorylation 
activity does not become more pronounced in advanced 
diabetes, but rather other accessory proteins may be 
more important in modulating myosin head extension in 
early diabetes, such as titin.
Limitations and future directions
In the present investigation we have presented data for 
ROCK1 and ROCK2 expression in the hearts of rats, 
however an important limitation of our study is we did 
not demonstrate specific activation of ROCK target pro-
teins to confirm increased ROCK activity. Other studies 
have reported that phosphorylation of downstream tar-
gets of ROCK including myosin light chain phosphatase 
targeting subunit 1 (MYPT1), LIM kinase (LIMK) and 
the ezrin/radixin/moesin (ERM) complex are elevated 
in the hearts and aorta of rats with advanced DCM [15, 
34, 35, 39, 51, 52], indicating increased activity of ROCK. 
Utilising whole-heart homogenates from the rats used 
in our studies of LV function we were not able to obtain 
clear western blot bands for LIMK or MYPT1 phos-
phoproteins to demonstrate elevated ROCK activity, in 
contrast to the previous studies that utilized aorta or iso-
lated cardiomyocytes [34, 35, 52]. In addition, previous 
studies in general detected low absolute levels of protein 
in advanced DCM [39, 51], whereas this study focused on 
early diabetes where expression levels might be expected 
to be lower. Considering this limitation of the current 
study future studies might benefit from investigating 
ROCK activity in isolated cardiomyocytes derived from 
diabetic rats at this early stage of DCM.
Although synchrotron SAXS was sensitive enough 
to be able to detect regional difference in CB dynamics, 
we did not assess regional changes in sarcomeric pro-
tein phosphorylation in the present study. In the hearts 
of rats post myocardial infarction, a reduction in MLC-2 
phosphorylation was shown to primarily occur in the 
endocardial myocytes, while no changes in MLC-2 phos-
phorylation were observed in the epicardium [53]. To 
the best of our knowledge, no such studies of regional 
changes in phosphorylation state have been conducted 
in the context of DCM. Future studies that examine 
regional changes in thick and thin filament accessory 
protein phosphorylation in parallel with regional SAXS 
recordings may further enhance our understanding of the 
pathogenesis of DCM.
The giant sarcomeric protein titin, (among various 
other functions) is an important regulator of CB kinet-
ics and dynamics in the myocardium by regulating car-
diomyocyte passive tension. Titin stiffness is primarily 
modulated via changes in titin isoform composition and 
or phosphorylation state. In rodent models of advanced 
T1DM and T2DM, titin isoform shifts from the stiffer 
N2B to the more elastic N2BA [54] and hypophospho-
rylation of the N2B isoform [55] are associated with 
diastolic dysfunction. Studies in isolated rat ventricular 
trabeculae have suggested that titin regulates actin–myo-
sin interaction by interfilament lattice spacing modula-
tion [56]. However, the role of interfilament spacing in 
the modulation of CB formation in length dependent 
activation remains controversial. Interestingly, Hanft 
et  al. [57] have shown that myosin head flexibility and 
extension towards to actin increases when titin is slack-
ened. The significantly smaller myosin interfilament 
spacing in the vehicle-treated diabetic group relative to 
the control group predicts that sarcomere length would 
be longer throughout the cardiac cycle (Figure  4), and 
therefore more taut, albeit within the normal sarcomere 
operating range. Whether ROCK activation influences 
myosin head extension and CB dynamics in vivo through 
changes in titin isoform and or phosphorylation state 
remains to be investigated.
Conclusion
In summary, we have confirmed that impairment in 
regional CB dynamics contribute to a reduction in devel-
oped force and LV contractile dysfunction in early DCM. 
Page 12 of 13Waddingham et al. Cardiovasc Diabetol  (2015) 14:92 
Furthermore, our current work suggests that increased 
ROCK expression and activation is involved in the devel-
opment of DCM as chronic inhibition of ROCK with 
fasudil preserved diastolic myosin mass transfer and 
prevented the decline in LV systolic function and force 
development. These findings appear to be largely inde-
pendent of changes in TnI, TnT, MLC-2 or MyBP-C pro-
tein phosphorylation. Nevertheless, these data suggest 
that ROCK is an important and promising therapeutic 
target for the treatment and management of DCM.
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